AUTHOR=den Hollander Bibiche , Rasing Anne , Post Merel A. , Klein Willemijn M. , Oud Machteld M. , Brands Marion M. , de Boer Lonneke , Engelke Udo F. H. , van Essen Peter , Fuchs Sabine A. , Haaxma Charlotte A. , Jensson Brynjar O. , Kluijtmans Leo A. J. , Lengyel Anna , Lichtenbelt Klaske D. , Østergaard Elsebet , Peters Gera , Salvarinova Ramona , Simon Marleen E. H. , Stefansson Kari , Thorarensen Ólafur , Ulmen Ulrike , Coene Karlien L. M. , Willemsen Michèl A. , Lefeber Dirk J. , Karnebeek Clara D. M. van 

TITLE=NANS-CDG: Delineation of the Genetic, Biochemical, and Clinical Spectrum

JOURNAL=Frontiers in Neurology

VOLUME=12

YEAR=2021

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2021.668640

DOI=10.3389/fneur.2021.668640

ISSN=1664-2295

ABSTRACT=<p><bold>Background:</bold> NANS-CDG is a recently described congenital disorder of glycosylation caused by biallelic genetic variants in <italic>NANS</italic>, encoding an essential enzyme in <italic>de novo</italic> sialic acid synthesis. Sialic acid at the end of glycoconjugates plays a key role in biological processes such as brain and skeletal development. Here, we present an observational cohort study to delineate the genetic, biochemical, and clinical phenotype and assess possible correlations.</p><p><bold>Methods:</bold> Medical and laboratory records were reviewed with retrospective extraction and analysis of genetic, biochemical, and clinical data (2016–2020).</p><p><bold>Results:</bold> Nine NANS-CDG patients (nine families, six countries) referred to the Radboudumc CDG Center of Expertise were included. Phenotyping confirmed the hallmark features including intellectual developmental disorder (IDD) (<italic>n</italic> = 9/9; 100%), facial dysmorphisms (<italic>n</italic> = 9/9; 100%), neurologic impairment (<italic>n</italic> = 9/9; 100%), short stature (<italic>n</italic> = 8/9; 89%), skeletal dysplasia (<italic>n</italic> = 8/9; 89%), and short limbs (<italic>n</italic> = 8/9; 89%). Newly identified features include ophthalmological abnormalities (<italic>n</italic> = 6/9; 67%), an abnormal septum pellucidum (<italic>n</italic> = 6/9; 67%), (progressive) cerebral atrophy and ventricular dilatation (<italic>n</italic> = 5/9; 56%), gastrointestinal dysfunction (<italic>n</italic> = 5/9; 56%), thrombocytopenia (<italic>n</italic> = 5/9; 56%), and hypo–low-density lipoprotein cholesterol (<italic>n</italic> = 4/9; 44%). Biochemically, elevated urinary excretion of <italic>N</italic>-acetylmannosamine (ManNAc) is pathognomonic, the concentrations of which show a significant correlation with clinical severity. Genotypically, eight novel <italic>NANS</italic> variants were identified. Three severely affected patients harbored identical compound heterozygous pathogenic variants, one of whom was initiated on experimental prenatal and postnatal treatment with oral sialic acid. This patient showed markedly better psychomotor development than the other two genotypically identical males.</p><p><bold>Conclusions:</bold> ManNAc screening should be considered in all patients with IDD, short stature with short limbs, facial dysmorphisms, neurologic impairment, and an abnormal septum pellucidum +/– congenital and neurodegenerative lesions on brain imaging, to establish a precise diagnosis and contribute to prognostication. Personalized management includes accurate genetic counseling and access to proper supports and tailored care for gastrointestinal symptoms, thrombocytopenia, and epilepsy, as well as rehabilitation services for cognitive and physical impairments. Motivated by the short-term positive effects of experimental treatment with oral sialic, we have initiated this intervention with protocolized follow-up of neurologic, systemic, and growth outcomes in four patients. Research is ongoing to unravel pathophysiology and identify novel therapeutic targets.</p>